secwatch.observer — SEC 8-K summary
======================================

Issuer:     LifeMD, Inc. (LFMD)
CIK:        0000948320
Form:       8-K
Filed at:   2023-06-22T23:59:59+00:00
Accession:  0001493152-23-022145
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LifeMD appoints William Febbo (OptimizeRx CEO) to Board; Galluppi resigns as director
--------------------------------------------------------------------------------

- Stefan Galluppi resigns from Board effective June 20, 2023; no disagreement; continues as Chief Innovation Officer.
- William Febbo appointed to Board; receives 75,000 restricted shares (half vest immediately) and 37,500 stock option.
- Febbo also entered consulting agreement May 30 for 375,000 restricted shares vesting quarterly through Nov 2024.
- Febbo is CEO of OptimizeRx (OPRX) with 25+ years in healthcare and digital health.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/948320/000149315223022145/0001493152-23-022145-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/948320/000149315223022145/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-022145

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer